Jacobs Levy Equity Management
ELVN icon

Jacobs Levy Equity Management’s Enliven Therapeutics ELVN Stock Holding History

Jacobs Levy Equity Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,449
Closed -$109K – 1060
2021
Q2 		$109K Hold
3,449
– – ﹤0.01% 1010
2021
Q1 		$116K Buy
+3,449
New +$175K ﹤0.01% 993

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jacobs Levy Equity Management's ELVN Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Enliven Therapeutics (ELVN) in Q3 2021, closing a stake of 3,449 shares — an estimated $109K sold.

Jacobs Levy Equity Management first reported a position in ELVN in Q1 2021 and held it in 2 quarters. The position peaked at $116K in Q1 2021. 38 funds tracked by Wall St. Rank hold ELVN as of Q3 2021.

  • Jacobs Levy Equity Management reported no remaining Enliven Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,449 Enliven Therapeutics shares in Q3 2021, an estimated $109K.
  • Jacobs Levy Equity Management first reported a position in Enliven Therapeutics in Q1 2021 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Enliven Therapeutics position peaked at $116K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.